137 related articles for article (PubMed ID: 33550112)
21. Coffee prevents fatty liver disease induced by a high-fat diet by modulating pathways of the gut-liver axis.
Vitaglione P; Mazzone G; Lembo V; D'Argenio G; Rossi A; Guido M; Savoia M; Salomone F; Mennella I; De Filippis F; Ercolini D; Caporaso N; Morisco F
J Nutr Sci; 2019; 8():e15. PubMed ID: 31037218
[TBL] [Abstract][Full Text] [Related]
22. Arginine/citrulline cycle changes in diet-induced rat model of non-alcoholic fatty liver disease.
Skrypnyk IМ; Maslova GS; Skrypnyk RІ; Gopko OF; Lymanets TV
Wiad Lek; 2020; 73(6):1087-1092. PubMed ID: 32723931
[TBL] [Abstract][Full Text] [Related]
23. Supplementation of sodium butyrate protects mice from the development of non-alcoholic steatohepatitis (NASH).
Jin CJ; Sellmann C; Engstler AJ; Ziegenhardt D; Bergheim I
Br J Nutr; 2015 Dec; 114(11):1745-55. PubMed ID: 26450277
[TBL] [Abstract][Full Text] [Related]
24. Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development.
Mouries J; Brescia P; Silvestri A; Spadoni I; Sorribas M; Wiest R; Mileti E; Galbiati M; Invernizzi P; Adorini L; Penna G; Rescigno M
J Hepatol; 2019 Dec; 71(6):1216-1228. PubMed ID: 31419514
[TBL] [Abstract][Full Text] [Related]
25. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
[TBL] [Abstract][Full Text] [Related]
26. Endotoxin Producers Overgrowing in Human Gut Microbiota as the Causative Agents for Nonalcoholic Fatty Liver Disease.
Fei N; Bruneau A; Zhang X; Wang R; Wang J; Rabot S; Gérard P; Zhao L
mBio; 2020 Feb; 11(1):. PubMed ID: 32019793
[TBL] [Abstract][Full Text] [Related]
27. Tauroursodeoxycholic acid inhibits intestinal inflammation and barrier disruption in mice with non-alcoholic fatty liver disease.
Wang W; Zhao J; Gui W; Sun D; Dai H; Xiao L; Chu H; Du F; Zhu Q; Schnabl B; Huang K; Yang L; Hou X
Br J Pharmacol; 2018 Feb; 175(3):469-484. PubMed ID: 29139555
[TBL] [Abstract][Full Text] [Related]
28. Supplementing L-Citrulline Can Extend Lifespan in
Rajcic D; Kromm F; Hernández-Arriaga A; Brandt A; Baumann A; Staltner R; Camarinha-Silva A; Bergheim I
Biomolecules; 2023 Oct; 13(11):. PubMed ID: 38002262
[TBL] [Abstract][Full Text] [Related]
29. Urea cycle metabolism: effects of supplemental ornithine or citrulline on performance, tissue amino acid concentrations and enzymatic activity in young pigs fed arginine-deficient diets.
Edmonds MS; Lowry KR; Baker DH
J Anim Sci; 1987 Sep; 65(3):706-16. PubMed ID: 3667436
[TBL] [Abstract][Full Text] [Related]
30. Inflammatory markers response to citrulline supplementation in patients with non-alcoholic fatty liver disease: a randomized, double blind, placebo-controlled, clinical trial.
Darabi Z; Darand M; Yari Z; Hedayati M; Faghihi A; Agah S; Hekmatdoost A
BMC Res Notes; 2019 Feb; 12(1):89. PubMed ID: 30767788
[TBL] [Abstract][Full Text] [Related]
31. The FATZO mouse, a next generation model of type 2 diabetes, develops NAFLD and NASH when fed a Western diet supplemented with fructose.
Sun G; Jackson CV; Zimmerman K; Zhang LK; Finnearty CM; Sandusky GE; Zhang G; Peterson RG; Wang YJ
BMC Gastroenterol; 2019 Mar; 19(1):41. PubMed ID: 30885145
[TBL] [Abstract][Full Text] [Related]
32. Effect of tryptophan supplementation on diet-induced non-alcoholic fatty liver disease in mice.
Ritze Y; Bárdos G; Hubert A; Böhle M; Bischoff SC
Br J Nutr; 2014 Jul; 112(1):1-7. PubMed ID: 24708895
[TBL] [Abstract][Full Text] [Related]
33. Hepatocellular carcinoma in a mouse model fed a choline-deficient, L-amino acid-defined, high-fat diet.
Ikawa-Yoshida A; Matsuo S; Kato A; Ohmori Y; Higashida A; Kaneko E; Matsumoto M
Int J Exp Pathol; 2017 Aug; 98(4):221-233. PubMed ID: 28895242
[TBL] [Abstract][Full Text] [Related]
34. Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation.
Porras D; Nistal E; Martínez-Flórez S; Pisonero-Vaquero S; Olcoz JL; Jover R; González-Gallego J; García-Mediavilla MV; Sánchez-Campos S
Free Radic Biol Med; 2017 Jan; 102():188-202. PubMed ID: 27890642
[TBL] [Abstract][Full Text] [Related]
35. Overactivation of intestinal sterol response element-binding protein 2 promotes diet-induced nonalcoholic steatohepatitis.
Malhotra P; Aloman C; Ankireddy A; Khadra H; Ooka K; Gill RK; Saksena S; Dudeja PK; Alrefai WA
Am J Physiol Gastrointest Liver Physiol; 2017 Nov; 313(5):G376-G385. PubMed ID: 28774869
[TBL] [Abstract][Full Text] [Related]
36. MicroRNA expression analysis in high fat diet-induced NAFLD-NASH-HCC progression: study on C57BL/6J mice.
Tessitore A; Cicciarelli G; Del Vecchio F; Gaggiano A; Verzella D; Fischietti M; Mastroiaco V; Vetuschi A; Sferra R; Barnabei R; Capece D; Zazzeroni F; Alesse E
BMC Cancer; 2016 Jan; 16():3. PubMed ID: 26728044
[TBL] [Abstract][Full Text] [Related]
37. Sodium butyrate attenuates high-fat diet-induced steatohepatitis in mice by improving gut microbiota and gastrointestinal barrier.
Zhou D; Pan Q; Xin FZ; Zhang RN; He CX; Chen GY; Liu C; Chen YW; Fan JG
World J Gastroenterol; 2017 Jan; 23(1):60-75. PubMed ID: 28104981
[TBL] [Abstract][Full Text] [Related]
38. Mitochondrial gene polymorphisms alter hepatic cellular energy metabolism and aggravate diet-induced non-alcoholic steatohepatitis.
Schröder T; Kucharczyk D; Bär F; Pagel R; Derer S; Jendrek ST; Sünderhauf A; Brethack AK; Hirose M; Möller S; Künstner A; Bischof J; Weyers I; Heeren J; Koczan D; Schmid SM; Divanovic S; Giles DA; Adamski J; Fellermann K; Lehnert H; Köhl J; Ibrahim S; Sina C
Mol Metab; 2016 Apr; 5(4):283-295. PubMed ID: 27069868
[TBL] [Abstract][Full Text] [Related]
39. Gypenosides improve the intestinal microbiota of non-alcoholic fatty liver in mice and alleviate its progression.
Huang X; Chen W; Yan C; Yang R; Chen Q; Xu H; Huang Y
Biomed Pharmacother; 2019 Oct; 118():109258. PubMed ID: 31545283
[TBL] [Abstract][Full Text] [Related]
40. Toll-like receptor 1 as a possible target in non-alcoholic fatty liver disease.
Baumann A; Nier A; Hernández-Arriaga A; Brandt A; Lorenzo Pisarello MJ; Jin CJ; Pilar E; Camarinha-Silva A; Schattenberg JM; Bergheim I
Sci Rep; 2021 Sep; 11(1):17815. PubMed ID: 34497333
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
